Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01242527 · ClinicalTrials.gov registry record · Phase 2
Epanova® for Lowering Very High Triglycerides
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 399
- Enrollment target
NCT01242527: Completed Phase 2 study, sponsored by AstraZeneca.
NCT01242527 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 399 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01242527, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 399 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
Primary Outcome
The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in triglycerides between placebo and the 2g/day, 3g/day and 4g/day Epanova groups
Interventions
- DRUG placebo
- DRUG omefas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 399 participants |
| Start Date | 2011-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
What the finished NCT01242527 record still lists
NCT01242527 is an interventional study that assigns participants to a tested intervention. The registered 399 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (200% higher).
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01242527 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01242527 about?
NCT01242527 is a clinical study titled "Epanova® for Lowering Very High Triglycerides". The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
What is the current status of trial NCT01242527?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 399 participants. The study started on 2011-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01242527?
The interventions under investigation include: placebo (DRUG), omefas (DRUG).
Who is sponsoring clinical trial NCT01242527?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01242527's enrollment target sits among peer trials
399 103rd of 2000 higher than 1,898 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia